Clinical Trials Browser

Completed × copanlisib × Clear all

NCT02705859 2026-04-13

Panther

Phase 1 Completed

HER2 Positive Breast Cancer

NCT04895579 2025-11-18

LCD

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT02367040 2025-10-14

CHRONOS-3

Phase 3 Completed

458 enrolled 22 charts

Lymphoma, Non-Hodgkin

NCT03711058 2025-09-16

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Phase 1/2 Completed

48 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Spinocerebellar Degenerations

NCT04462471 2025-09-08

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Phase 1 Completed

8 enrolled 8 charts

EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT03484819 2025-03-03

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Phase 2 Completed

12 enrolled 13 charts

Lymphoma, Large B-Cell, Diffuse

NCT05217914 2024-10-24

A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions

Recurrence

NCT01660451 2024-07-17

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Phase 2 Completed

227 enrolled 25 charts

Lymphoma, Non-Hodgkin

NCT02369016 2023-11-18

CHRONOS-2

Phase 3 Completed

25 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT03735628 2023-10-06

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

Phase 1 Completed

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

NCT02342665 2023-01-20

Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Phase 1/2 Completed

Lymphoma, Non-Hodgkin

NCT03877055 2022-12-14

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

Phase 1/2 Completed

8 enrolled 7 charts

Lymphoma, Mantle-Cell

NCT03517956 2022-07-14

ROCOCO

Phase 1 Completed

Neoplasm Metastasis

NCT03052933 2022-06-10

Copanlisib and Gemcitabine in Relapsed/Refractory PTCL

Phase 1/2 Completed

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT02728258 2022-02-15

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Phase 2 Completed

11 enrolled 12 charts

Carcinoma, Endometrioid

NCT02631590 2021-08-04

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

Phase 2 Completed

24 enrolled 11 charts

Gastrointestinal

Digestive System Neoplasms, Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

NCT03498430 2021-05-19

Copanlisib Chinese PK Study

Phase 1 Completed

Lymphoma, Non-Hodgkin

NCT03172884 2021-04-28

Study of Copanlisib in Hepatic or Renal Impairment

Phase 1 Completed

30 enrolled 20 charts

Hepatic Insufficiency, Renal Insufficiency

NCT02253420 2020-12-14

COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients

Phase 1 Completed

Lymphoma, Non-Hodgkin

NCT02391116 2019-01-04

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2 Completed

67 enrolled 29 charts

Lymphoma, Large B-Cell, Diffuse

NCT01411410 2017-10-11

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Phase 1 Completed

Neoplasms

NCT00962611 2017-10-06

BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Phase 1 Completed

Neoplasms

NCT02155582 2017-06-16

Copanlisib Pharmacodynamic Study

Phase 1 Completed

Lymphoma, Non-Hodgkin

NCT01392521 2015-04-17

Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer

Phase 1 Completed

Neoplasms